BE.Amycon Registry UZ Leuven

Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · May 21, 2025

Keywords

ClinConnect Summary

The BE.Amycon Registry UZ Leuven is a study that aims to collect important health information about patients diagnosed with amyloidosis, a condition where abnormal proteins build up in the body. This research will help doctors better understand how the disease presents, how it progresses over time, the treatments patients receive, and their responses to these treatments. By gathering this data, researchers hope to improve care for patients with all types of amyloidosis.

To participate in this study, individuals must be 18 years or older and have a confirmed diagnosis of amyloidosis, whether newly diagnosed or already in follow-up care. Participants will need to provide their consent and sign a form agreeing to take part in the study. The study is expected to run from June 1, 2025, to December 31, 2027. If you or a loved one is considering joining, it’s important to know that the study is not currently recruiting participants, but it will be open to everyone regardless of gender.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or older
• • Provide consent and sign informed consent form
• • Confirmed diagnosis of amyloidosis (any subtype), systemic and/or localised
• • Newly diagnosed or in follow-up during the study time-frame (1 JUN 2025 until 31 DEC 2027)
• Exclusion Criteria:
• • Not able to provide informed consent
• • Not willing to sign informed consent